Chaiyot Tanrattana

Antinol® Latest Studies

Sorted by recent

What’s better than fun? Double the fun! That’s exactly what 22Fun delivers with its incredible mix of games and opportunities. Whether you’re spinning the reels on slots or trying your hand at a live casino table, 22fun guarantees non-stop entertainment. This platform knows how to keep players smiling with its engaging design and rewarding features. Why just play when you can truly have fun with every bet?

Filter Studies by Smart Tags

Bone & JointCardiovascularCase Study & ProceedingCatDogEAB 277™EfficacyExotic PetImmunologyNeuro & BehaviorOphthalmologyOralRabbitRenalRespiratoryRodentSafetySkinUTI

Smart Search

DogSkin

Clinical study of PCSO-524 (ANTINOL™) as neutraceutical in canine allergic skin disease

Oral Presentation at The World Veterinary Congress WVAC 2018
Authors:
Chaiyot Tanrattana

This study included 31 allergic dogs with chronic pruritis with other skin diseases excluded.

Dogs were split into 3 treatment groups based on degree of pruritis, distribution, extension of the lesions and skin and coat condition; Group 1: mild, Group 2: moderate, and Group 3: severe.

All dogs received PCSO-524 loading dose 10 mg/kg q12hr PO for 2 weeks followed by a maintenance dose of 10 mg/kg q24hr PO.

All dogs were evaluated at 2, 4, 8, 12 and 16 weeks for clinical response. The assessment made by the owners (PVAS Score) and Vets (CADESI-03 score).

 

 

. . . VIEW

 

. . . VIEW

Updated Study Topics

New researches and publications related to PCSO-524® and its result in clnical test submitted by veterinarians on the global conferences every year and the data keeps growing with more studies conducted

 

Discover More Studies
Click to see the library